ANTIESTROGENIC TREATMENT OF ADVANCED AND RECURRENT CARCINOMA-CORPORIS-UTERI - A PHASE-II STUDY OF TOREMIFENE

  • 1 March 1990
    • journal article
    • research article
    • Vol. 10  (2A) , 323-325
Abstract
The antitumor efficacy and toxicity of a new antiestrogenic substance - toremifene - were investigated in a phase II study. Twenty-six patients were eligible for final evaluation (6 primary and 20 recurrent disease). A daily dose of 200 mg toremifene was given orally. Treatment continued for at least 3 months, until progression or significant side-effects were encountered. The response rate was 35% (3 CR and 6 PR). Six patients had NC and 11 did not respond to the treatment. The median duration of responses for CR was 10+ months (range 3+-19) and for PR 4 months (range 3+-16). The treatment seems to be well tolerated and effective.